Login / Signup

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Stephen P HackWendy VerretSohail MullaBo LiuYulei WangTeresa MacarullaZhenggang RenAnthony B El-KhoueiryAndrew X Zhu
Published in: Therapeutic advances in medical oncology (2021)
NCT identifier: NCT04677504; EUDRACT number: 2020-003759-14.
Keyphrases
  • papillary thyroid
  • squamous cell
  • locally advanced
  • open label
  • lymph node metastasis
  • metastatic colorectal cancer
  • squamous cell carcinoma
  • childhood cancer
  • young adults
  • radiation therapy
  • chemotherapy induced